About 200 COVID-19 vaccines are undergoing clinical and preclinical trials, Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, said at a briefing on Monday.
“Almost 200 COVID-19 vaccines are currently undergoing clinical and preclinical trials. The history of vaccines shows us that some will fail and others will be successful,” he said.
In this regard, the WHO Director-General stressed the importance of states joining the WHO and GAVI program called COVAX Facility, collecting data on all candidate vaccines.
According to GAVI data, as of September 21, 156 economies have already joined the COVAX Facility, including 64 high-income countries, representing 64% of the world’s population. The list, in particular, includes 27 EU countries, Norway, Iceland, and the United Kingdom. Russia, the United States, and China are not members of the COVAX Facility program.
“The COVAX Facility program is aimed at dialogue with all countries, and we will continue to communicate with all countries to make sure that vaccines if they appear, will be available to everyone,” GAVI Executive Director Seth Berkley commented on the situation.
It is expected that COVAX Facility will start signing agreements with manufacturers and developers of vaccines to ensure that by the end of 2021, there is enough medicine for everyone as soon as it becomes available.